Lab Company Shares Dive as FDA Pivots Away From Animal Testing

(Updates Charles River share move, adds other peers, AI movers, more details from FDA.)

The FDA said it plans to phase out animal testing requirements for monoclonal antibodies and other drugs, replacing them with “more effective, human-relevant methods.”

• Shares in Charles River Laboratories, a leading provider of research animal models, plunged by a one-day record of 28% to the lowest since March 2020
  • Among other contract-research peers, LabCorp closed lower by 5.2%, while microcap stock Inotiv lost 50%
• Animal-testing regulations to be “reduced, refined, or potentially replaced using a range of approaches, including AI-based computational models of toxicity and ...